All Articles
Biotech

Atossa Therapeutics Has Begun Dosing Patients In New Breast Cancer Trial

September 9, 2024
x min read
3D rendering of a mammogram machine

A new clinical trial has started for breast cancer patients that has the potential to validate an innovative therapeutic treatment. And a publicly traded company is behind it.

What’s happening:

  • Atossa Therapeutics (NASDAQ: ATOS) has officially dosed their first patient in their clinical trial partnership with Quantum Leap Healthcare Collaborative which is aiming to validate Atossa’s proprietary (Z)-Endoxifen drug in combination with Abemaciclib for breast cancer treatment

Why it matters:

  • The study is focused on breast cancer patients with newly diagnosed estrogen receptor-positive invasive breast cancer whose tumours are expected to be sensitive to endocrine therapy but are very unlikely to experience any benefit at all from traditional chemotherapy
  • Atossa Therapeutics proprietary (Z)-Endoxifen could represent a potential breakthrough for a new drug treatment that is both effective and safe for these specific types of breast cancer patients

By the numbers:

  • The study will have 80 individual participants, separated across 2 different patient cohorts
  • Both cohorts of women will be dosed with 80mg of (Z)-Endoxifen once daily and 150mg of Abemaciclib twice daily for 24 weeks prior to surgery

Going deeper:

  • Atossa Therapeutics is collaborating with Quantum Leap Healthcare Collaborative on the new clinical trial, who is a leading edge cancer charity that was originally formed by medical researchers at the University of California, San Francisco and Silicon Valley technology entrepreneurs
  • Because patients who are diagnosed with estrogen receptor-positive invasive breast cancer typically do not respond well to chemotherapy or immunotherapy, there is a large clinical risk for patients as well as a significant unmet medical need that does not currently have many approved therapeutic treatment options that have proven to be effective and safe

Disclaimer

The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by Atossa Therapeutics for a media campaign, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of Atossa Therapeutics without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.

Discover the world's most disruptive early stage companies with 35,000+ investors.

The markets and trends that matter, made simple.

Join top talent at the world's most respected institutions, companies, and venture capital funds.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.